Current status of antiretroviral therapy

Zelalem Temesgen, David Warnke, Mary J. Kasten

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.

Original languageEnglish (US)
Pages (from-to)1541-1554
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume7
Issue number12
DOIs
StatePublished - Aug 2006

Fingerprint

Anti-Retroviral Agents
Guidelines
Pharmaceutical Preparations
Therapeutics

Keywords

  • Antiretroviral therapy
  • Antiretrovirals
  • Chemokine receptor antagonists
  • Entry inhibitors
  • Fusion inhibitors
  • Highly active antiretroviral therapy
  • HIV
  • Integrase inhibitors
  • Maturation inhibitors
  • Non-nucleoside analogue reverse transcriptase inhibitors
  • Nucleoside analogue reverse transcriptase inhibitors
  • Protease inhibitors
  • Treatment guidelines

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Current status of antiretroviral therapy. / Temesgen, Zelalem; Warnke, David; Kasten, Mary J.

In: Expert Opinion on Pharmacotherapy, Vol. 7, No. 12, 08.2006, p. 1541-1554.

Research output: Contribution to journalArticle

Temesgen, Zelalem ; Warnke, David ; Kasten, Mary J. / Current status of antiretroviral therapy. In: Expert Opinion on Pharmacotherapy. 2006 ; Vol. 7, No. 12. pp. 1541-1554.
@article{b25533effef44c3682a7c7271c531d1f,
title = "Current status of antiretroviral therapy",
abstract = "At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.",
keywords = "Antiretroviral therapy, Antiretrovirals, Chemokine receptor antagonists, Entry inhibitors, Fusion inhibitors, Highly active antiretroviral therapy, HIV, Integrase inhibitors, Maturation inhibitors, Non-nucleoside analogue reverse transcriptase inhibitors, Nucleoside analogue reverse transcriptase inhibitors, Protease inhibitors, Treatment guidelines",
author = "Zelalem Temesgen and David Warnke and Kasten, {Mary J.}",
year = "2006",
month = "8",
doi = "10.1517/14656566.7.12.1541",
language = "English (US)",
volume = "7",
pages = "1541--1554",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Current status of antiretroviral therapy

AU - Temesgen, Zelalem

AU - Warnke, David

AU - Kasten, Mary J.

PY - 2006/8

Y1 - 2006/8

N2 - At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.

AB - At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.

KW - Antiretroviral therapy

KW - Antiretrovirals

KW - Chemokine receptor antagonists

KW - Entry inhibitors

KW - Fusion inhibitors

KW - Highly active antiretroviral therapy

KW - HIV

KW - Integrase inhibitors

KW - Maturation inhibitors

KW - Non-nucleoside analogue reverse transcriptase inhibitors

KW - Nucleoside analogue reverse transcriptase inhibitors

KW - Protease inhibitors

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=33747078251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747078251&partnerID=8YFLogxK

U2 - 10.1517/14656566.7.12.1541

DO - 10.1517/14656566.7.12.1541

M3 - Article

C2 - 16872258

AN - SCOPUS:33747078251

VL - 7

SP - 1541

EP - 1554

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 12

ER -